Role of CXCR3 for CD8+ T cells in cancer immunotherapy
CXCR3 对 CD8 T 细胞在癌症免疫治疗中的作用
基本信息
- 批准号:8223306
- 负责人:
- 金额:$ 31.8万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-05-01 至 2014-02-28
- 项目状态:已结题
- 来源:
- 关键词:AdjuvantAntigensBasic ScienceBiologicalBiologyCD8-Positive T-LymphocytesCD8B1 geneCXCR3 geneCancer ControlCancer VaccinesCell MaintenanceCell physiologyCellsClinicalCorrelative StudyCytotoxic T-LymphocytesDataDiseaseEvaluationFailureGenerationsHomingHumanImmigrationImmuneImmunizationImmunobiologyImmunologicsImmunotherapyIn VitroInfiltrationInterventionKnowledgeLyticMarker VaccinesMediatingMemoryMetastatic MelanomaMolecularNatureNeoplasm MetastasisOutcomePatientsPhenotypePopulationProteinsRegulationResearchRoleSpecific qualifier valueSpecificityStudy modelsT memory cellT-Cell ActivationT-LymphocyteTherapeuticTissue SampleTissuesTumor BiologyVaccinatedVaccinationVaccinesVariantWorkbasecancer immunotherapycell motilitychemokine receptorcohortconventional therapydesignexpectationhuman tissueimmunogenicmelanocytemelanomamigrationmouse modelprognosticresponsesuccesstumor
项目摘要
Given the recalcitrant nature of melanoma to conventional therapies, there exists a critical need
for successful clinical immunotherapy to treat metastatic melanoma. The objective of most
clinical immunotherapy trials has been to generate maximal numbers of circulating tumor-
specific cytotoxic T lymphocytes (CTL), predicated on the notion that "more is better." However,
the correlation between magnitude of vaccine-induced CD8+ T cells and the objective clinical
responses remains weak, suggesting that the inefficacy of immune therapy results from the
qualitative failure of vaccine-induced T cells to efficiently activate, infiltrate tumor, and develop
robust memory populations. Therefore, we have examined several qualitative aspects of tumor
Ag-specific T cells from melanoma patients that have been vaccinated with multiple melanocyte
differentiation protein-derived antigens in an adjuvant setting. We demonstrated a significant
association between the expression of CXCR3 by circulating tumor-specific CD8+ T cells and
the maintenance of disease-free status or survival, suggesting either that CXCR3 expression a)
is functionally required for the T cell-mediated immunologic control of metastatic tumors, or b)
serves as a marker of qualitatively-superior anti-tumor T cells. In the present proposal, we
delineate three aims that will expand upon our initial findings and evaluate the mechanisms by
which CXCR3 and its biological axis of molecules act to enhance immune-mediated tumor
control. Specifically, we will relate CXCR3 expression in the human CD8 compartment to 1)
immunization-induced polarization phenotype; 2) anti-tumor functionality; 3) and access to
metastatic tumor compartments. We will use human tissues and samples for correlative studies
and mouse models for mechanistic studies. Key deliverables of this research will include basic
science knowledge with translational potential, including: 1) enhanced understanding of the
regulation of CXCR3 expression and T cell polarization in human CD8+ T cells; 2) evaluation of
the prognostic utility of CXCR3 expression as a marker of vaccine response and means to
prospectively evaluate patient-specific response potential; and 3) new immunologic targets for
intervention, so as to optimize the therapeutic potential of immunogenic vaccines.
鉴于黑色素瘤对常规疗法的排斥性,
用于治疗转移性黑色素瘤的成功临床免疫疗法。大多数人的目标
临床免疫治疗试验已经产生了最大数量的循环肿瘤-
特异性细胞毒性T淋巴细胞(CTL),基于“越多越好”的概念。“然而,
疫苗诱导的CD 8 + T细胞数量与客观临床
反应仍然很弱,这表明免疫治疗的无效性是由于
疫苗诱导的T细胞不能有效地活化、浸润肿瘤和发展
强大的记忆群体。因此,我们检查了肿瘤的几个定性方面,
已接种多种黑素细胞的黑色素瘤患者的Ag特异性T细胞
分化蛋白衍生的抗原在佐剂环境中。我们展示了一个重要的
循环肿瘤特异性CD 8 + T细胞表达CXCR 3与
维持无病状态或存活,表明CXCR 3表达a)
是转移性肿瘤的T细胞介导的免疫控制功能上所需的,或B)
作为优质抗肿瘤T细胞的标志物。在本提案中,我们
描述三个目标,将扩大我们的初步研究结果和评估机制,
其中CXCR 3及其生物学轴分子的作用是增强免疫介导的肿瘤
控制具体而言,我们将人CD 8区室中的CXCR 3表达与1)
免疫诱导极化表型; 2)抗肿瘤功能; 3)和获得
转移性肿瘤隔室。我们将使用人体组织和样本进行相关研究
和用于机理研究的小鼠模型。这项研究的主要成果将包括基本的
具有转化潜力的科学知识,包括:1)加强对
人CD 8 + T细胞中CXCR 3表达和T细胞极化的调节; 2)评估
CXCR 3表达作为疫苗应答标志物的预后效用以及
前瞻性评估患者特异性反应潜力;和3)新的免疫靶点,
干预,以优化免疫原性疫苗的治疗潜力。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID W. MULLINS其他文献
DAVID W. MULLINS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID W. MULLINS', 18)}}的其他基金
Beta-adrenergic mediated suppression of T cell chemotaxis by cancers
β-肾上腺素能介导的癌症对 T 细胞趋化性的抑制
- 批准号:
9306460 - 财政年份:2017
- 资助金额:
$ 31.8万 - 项目类别:
Role of CXCR3 for CD8+ T cells in cancer immunotherapy
CXCR3 对 CD8 T 细胞在癌症免疫治疗中的作用
- 批准号:
8444268 - 财政年份:2009
- 资助金额:
$ 31.8万 - 项目类别:
Role of CXCR3 for CD8+ T cells in cancer immunotherapy
CXCR3 对 CD8 T 细胞在癌症免疫治疗中的作用
- 批准号:
8337135 - 财政年份:2009
- 资助金额:
$ 31.8万 - 项目类别:
Role of CXCR3 for CD8+ T cells in cancer immunotherapy
CXCR3 对 CD8 T 细胞在癌症免疫治疗中的作用
- 批准号:
7654304 - 财政年份:2009
- 资助金额:
$ 31.8万 - 项目类别:
Role of CXCR3 for CD8+ T cells in cancer immunotherapy
CXCR3 对 CD8 T 细胞在癌症免疫治疗中的作用
- 批准号:
8033258 - 财政年份:2009
- 资助金额:
$ 31.8万 - 项目类别:
相似国自然基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
- 批准号:2022J011295
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
- 批准号:30801055
- 批准年份:2008
- 资助金额:19.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
- 批准号:
BB/Y006224/1 - 财政年份:2024
- 资助金额:
$ 31.8万 - 项目类别:
Research Grant
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
- 批准号:
480030 - 财政年份:2023
- 资助金额:
$ 31.8万 - 项目类别:
Operating Grants
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
- 批准号:
10083718 - 财政年份:2023
- 资助金额:
$ 31.8万 - 项目类别:
Small Business Research Initiative
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
- 批准号:
MR/X009254/1 - 财政年份:2023
- 资助金额:
$ 31.8万 - 项目类别:
Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
- 批准号:
22KJ1758 - 财政年份:2023
- 资助金额:
$ 31.8万 - 项目类别:
Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
- 批准号:
BB/Y000927/1 - 财政年份:2023
- 资助金额:
$ 31.8万 - 项目类别:
Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
- 批准号:
10795212 - 财政年份:2023
- 资助金额:
$ 31.8万 - 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
- 批准号:
23K18249 - 财政年份:2023
- 资助金额:
$ 31.8万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
- 批准号:
10735075 - 财政年份:2023
- 资助金额:
$ 31.8万 - 项目类别:
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
- 批准号:
10645989 - 财政年份:2023
- 资助金额:
$ 31.8万 - 项目类别:














{{item.name}}会员




